You are here

  • Home
  • Archive
  • Volume 20, Issue 5
  • Blood pressure lowering in patients with type 2 diabetes improves cardiovascular events including mortality, but more intensive lowering to systolic blood pressure less than 130 mm Hg is associated with further reduction in stroke and albuminuria without…

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review with meta-analysis
Blood pressure lowering in patients with type 2 diabetes improves cardiovascular events including mortality, but more intensive lowering to systolic blood pressure less than 130 mm Hg is associated with further reduction in stroke and albuminuria without further reduction in cardiac events
  1. Bora Toklu,
  2. Sripal Bangalore
  1. Department of Cardiology, New York University School of Medicine, New York, New York, USA
  1. Correspondence to : Dr Sripal Bangalore, Department of Cardiology, New York University School of Medicine, New York, NY 10016, USA; sripalbangalore{at}gmail.com

https://doi.org/10.1136/ebmed-2015-110197

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603–15.OpenUrlCrossRefPubMed

    Context

    Hypertension and diabetes are independent risk factors for cardiovascular disease.1 Although lowering blood pressure (BP) reduces cardiovascular events,1 thresholds to initiate antihypertensive therapy and BP targets have been areas of controversy. Until recently, guideline recommendations for BP targets have been more stringent in patients with diabetes.

    Methods

    Emdin and colleagues report information from a systematic review of 45 randomised trials. The trials included 104 586 participants with diabetes with higher or lower BP targets. They compared antihypertensive medications with placebo or two antihypertensive medications in this patient group. Outcomes assessed included macrovascular and microvascular outcomes.

    Findings

    Overall, lowering systolic BP (SBP) by …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.